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In vitro incubation of nanomaterials with plasma offer insights on biological interactions, but
cannot fully explain the in vivo fate of nanomaterials. Here, we use a library of polymer
nanoparticles to show how physicochemical characteristics inﬂuence blood circulation and
early distribution. For particles with different diameters, surface hydrophilicity appears to
mediate early clearance. Densities above a critical value of approximately 20 poly(ethylene
glycol) chains (MW 5 kDa) per 100 nm2 prolong circulation times, irrespective of size. In
knockout mice, clearance mechanisms are identiﬁed for nanoparticles with low and high
steric protection. Studies in animals deﬁcient in the C3 protein showed that complement
activation could not explain differences in the clearance of nanoparticles. In nanoparticles
with low poly(ethylene glycol) coverage, adsorption of apolipoproteins can prolong
circulation times. In parallel, the low-density-lipoprotein receptor plays a predominant role in
the clearance of nanoparticles, irrespective of poly(ethylene glycol) density. These results
further our understanding of nanopharmacology.
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Upon dilution in plasma, nanoparticles rapidly adsorbproteins1. It is believed that this protein corona affectshow nanoparticles are perceived by biological systems2, 3.
In an elegant proteomics study performed on uncoated silica
and poly(styrene) nanoparticles, Tenzer et al.1 showed that
equilibrium in the protein corona is reached a few minutes after
dilution in plasma. Furthermore, they showed that this corona
affects how nanomaterials interact with platelets and blood cells.
In biological systems, interactions with proteins ensure adequate
distribution of nanoparticles to the desired target. For some
siRNA-loaded lipoplexes, interactions with apolipoproteins are
essential for the targeting of hepatocytes4, 5. In other cases, pro-
tein adsorption on targeted silica nanoparticles induces a loss of
selectivity in receptor-mediated endocytosis6. In clinical settings,
interactions of nanomedicines with proteins, notably via the
activation of the complement system, can trigger pseudo-allergic
reactions7. For all these reasons, understanding how
nanoparticles interact with the biological milieu is crucial for the
rational development of drug-delivery systems.
Nanoparticles prepared with poly(ethylene glycol)-b-poly(lactic
co glycolic acid) (PEG–PLGA) copolymers have a long history in
drug delivery8 and have recently reached clinical maturity9.
In light of the data obtained with model nanoparticles1, 6, 10, 11,
it is therefore particularly interesting to understand how
physicochemical properties affect the biological fate of these
clinically relevant particles.
Here, we show that the PEG density on the surface of
PEG–PLGA nanoparticles is a key determinant of their early
clearance in vivo. We identify a PEG density threshold below
which blood clearance is rapid. Further PEGylation beyond
this value does not signiﬁcantly prolong the circulation times
measured over a period of 6 h. This PEG density threshold,
measured as the number of PEG chains per 100 nm2, remains
similar for nanoparticles with diameters of 55, 90, and 140 nm.
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Fig. 1 Nanoparticles with different PEG densities and sizes prepared by combinatorial synthesis of PEG–PLGA and PLGA copolymers. a By self-assembly,
polymer precursors form core-shell nanoparticles. Different sizes and PEG contents can be obtained by combining diblock and uniblock precursors.
Analysis by 1H-NMR spectroscopy in different solvents can determine the PEG content in the nanoparticles and in the hydrated shell. b Most of the PEG
used in the polymer precursor solution is incorporated in the nanoparticles. c For nanoparticles with diameters of 55, 90, and 140 nm, whose core is non-
solvated (i.e., in D2O), most of the total PEG signal is detectable, suggesting that most of the hydrophilic polymer is hydrated in the shell. d Joining
combinatorial synthesis and careful 1H-NMR characterization, a library of nanoparticles with different sizes and PEG densities can be prepared
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Using transgenic mice, and animals with different protein
phenotypes, we highlight that complement activation cannot
explain the differences observed between nanoparticles with fast
and slow clearances. Interestingly, apolipoproteins responsible
for the trafﬁcking of lipids in the bloodstream interact with
nanoparticles and appear to impact on their clearance.
Results
Nanoparticle synthesis and characterization. Using nanopreci-
pitation and combinatorial synthesis12, PEG–PLGA nanoparticles
can be synthesized with different physicochemical properties in a
robust and reproducible manner. Furthermore, because they are
prepared using structurally simple copolymers, in the absence of
other surfactants, proton nuclear magnetic resonance (1H-NMR)
can be used to monitor their composition and quantitatively
characterize their outside polymer shell13, 14. PEG contents
assessed by 1H-NMR were in good agreement with those
measured by a colorimetric, iodine-based PEG quantiﬁcation
method (Supplementary Fig. 1). Herein, PEG–PLGA nano-
particles with different sizes (55–140 nm) and PEG densities
(10–50 PEG chains per 100 nm2) were synthesized through
nanoprecipitation of PLGA and PEG–PLGA copolymers (Fig. 1
and Supplementary Table 2). A PEG molecular weight of 5000
was chosen, in accordance with clinically advanced PEG–PLGA
nanoparticles9 and other systems that appear to necessitate longer
PEG chains than lipid-based platforms15–17. PEG content after
puriﬁcation was mostly proportional to the amounts of PEG used
in the initial solution, and more than 90% of the total PEG
was found solvated in the outside shell (Fig. 1b, c). Using the
nanoprecipitation method, it was therefore possible to prepare
particles with nearly neutral zeta potential (between 0 and
−5 mV), differing only in size or PEG density (Fig. 1d,
and Supplementary Fig. 2). To facilitate their detection in vivo,
these nanoparticles were also labeled with small amounts of
[14C]-PLGA.
Circulation in wild-type animals. The circulation proﬁle of
[14C]-labeled nanoparticles was monitored for 6 h following
intravenous injection to healthy Balb/c mice18, 19. In agreement
with the general consensus in the literature20, 21, for particles of
the same size, greater PEGylation decreases early clearance from
the bloodstream (Fig. 2). Interestingly, within that 6-h time
frame, little beneﬁt is gained from further increasing the amount
of PEG in the system, once the polymer shell reaches around 20
PEG chains per 100 nm2. In other words, two clearance rates are
observed: fast and slow, for nanoparticles with densities below
and above 20 PEG chains per 100 nm2, respectively. Distribution
to the liver and spleen is also different between nanoparticles with
PEG densities above and below that threshold (Supplementary
Fig. 3). Since the clearance mechanisms of Balb/c mice might be
different from those of other animal strains22, this critical PEG
density value was also conﬁrmed in C57Bl/6 mice and rats
(Supplementary Figs. 4 and 5), conﬁrming the consistency of
these observations across multiple preclinical models. Regarding
parameters commonly used to describe PEG density20, 21,
the threshold of 20 PEG chains per 100 nm2 is equivalent to a
distance between PEG5k chains of 2.5 nm and a PEG layer
thickness of 10.6 nm. These values correspond to a dense PEG
brush conformation and appear consistent with the literature on
long-circulating liposomes (Supplementary Discussion), but seem
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Fig. 2 A PEG density threshold of 20 PEG chains per 100 nm2 is necessary to avoid early clearance from the bloodstream. a The early circulation of
nanoparticles with diameters of 55, 90, and 140 nm appears to be mainly affected by the density of PEG chains on their surface. Below a threshold around
20 PEG chains per 100 nm2, the nanoparticles are cleared rapidly; above this value, the nanoparticles exhibit roughly the same circulation proﬁles,
irrespective of their diameter or extent of PEGylation. b Pharmacokinetic analysis of blood exposure (AUC0–6h) and elimination constants (ke) also highlight
the presence of a threshold above which greater PEG coverage does not increase beneﬁts on prolonging the circulation of nanoparticles. Values are means
± SD (n= 3–5); numbers in blue represent the PEG chains per 100 nm2 of surface
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much lower than the PEG density required to obtain long-
circulating poly(styrene) nanoparticles20. These discrepancies
could be explained by differences in the hydrophobicity of
the core, or by the methodologies used to quantify the PEG
contents.
Compellingly, for particles with diameters of 55, 90, and
140 nm, the threshold of PEG density at which clearance
slows down appears to be the same (i.e., around 20 PEG chains
per 100 nm2). In addition, during this relatively short study,
particles with PEG densities above this critical value exhibit very
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similar circulation proﬁles; that is, similar area under the blood
concentration vs. time curve (AUC0–6h) and elimination
constants (ke) (Fig. 2, Supplementary Figs. 4 and 5). This suggests
that the surface makeup of the particles, and not their dimension,
is responsible for their removal from the bloodstream. This
observation contrast with data obtained with PEGylated gold and
polystyrene particles of different sizes (the former being coated
with PEG1k, PEG2k, and PEG10k23 and the latter by physically
adsorbing tocopheryl-PEG1k-succinate24) as well as non-
PEGylated gold and chitosan nanoparticles25, 26. Differences in
methods, material properties, and preparation strategies, notably
regarding PEGylation (Supplementary Discussion) or possible
differences in shell stability in vivo27, might explain these
variations. The size range studied here (55–140 nm) remains
signiﬁcantly larger than that of adsorbing proteins and compar-
able to the diameters of many systems engineered for drug
delivery and imaging applications.
In vivo protein corona. In many reports, the protein corona
formed on metal28, lipid29, and polymer nanoparticles11 appears
generally composed of complement proteins and apolipoproteins
with or without immunoglobulins. In a comprehensive review on
the subject, Monopoli et al. refer to the presence of soft and
hard protein coronas2, i.e., proteins that are loosely or tightly
associated with the nanoparticles, respectively. Because only
strong interactions can withstand puriﬁcation processes, the hard
corona is likely easier to characterize experimentally2. Here, the
hard corona formed in the bloodstream on 90-nm nanoparticles
within 15 min of their intravenous injection was characterized
(particles with 15, 18, 25, and 45 PEG chains per 100 nm2,
Supplementary Figs. 6 and 7). In this experiment, the relative
abundance of protein compared to plasma, and not their
percentage distribution in the corona layer, was analyzed by
Tandem Mass Tag (TMT)-label proteomics analysis (Supple-
mentary Method). On the surface of nanoparticles with slow and
fast clearance alike, various apolipoproteins were signiﬁcantly
enriched, a phenomenon observed by others2. Although no
obvious dichotomous differences were found in the proteomic
footprint of nanoparticles with fast and slow clearance, the
adsorption of apolipoprotein E (ApoE) appeared to be dependent
on PEG density (Supplementary Fig. 7). For this protein, nano-
particles with higher PEG densities appear to have lower relative
abundance of ApoE.
Effect of complement activation. Beyond what can be observed
through proteomics analysis, in vivo experiments can also offer
insights on how protein interactions affect the overall biological
fate of nanoparticles. For example, the blood exposure of
nanoparticles with fast and slow clearances can be compared
among animals with different phenotypes in blood proteins. Like
other nanomaterials, PEGylated PLGA nanoparticles are mild
complement activators in vitro, irrespective of their PEG density
(Supplementary Fig. 8)30. However, upon intravenous injection,
they fail to markedly elevate the circulating levels of C5b-9, the
end product of the complement cascade (Supplementary Fig. 9).
To elucidate whether the complement cascade can partly
explain the large differences in circulation times observed with
nanoparticles with fast and slow clearance, the blood circulation
proﬁles of animals deﬁcient in complement protein 3 (C3−/−)
were compared to those obtained in wild-type mice (C57Bl/6)
(Fig. 3a). The C3 protein is essential to all three complement
activation pathways; these double-knockout animals have unde-
tectable levels of C3 protein and no residual functional comple-
ment activity, according to ELISA and hemolytic assays,
respectively31. In these mice, no increase in circulation times were
observed when the cascade is abrogated, suggesting that this part
of the innate immunity cannot explain the signiﬁcant differences
in the clearance of nanoparticles with PEG densities above and
below 20 PEG chains per 100 nm2 (Fig. 3a). Correspondingly,
similar amounts of C3 and other complement components were
measured by proteomics on nanoparticles with fast and slow
clearances (Supplementary Fig. 6c). Together, this suggests
that the deposition of complement proteins on the surface of
PEG–PLGA nanoparticles is too mild to impact their circulation
times, irrespective of their PEG density. PEGylated liposomes
are also mild complement activators: despite their very
long circulation times32, they can trigger pseudo-allergic
infusion reactions by activating the cascade7, 33. In contrast,
Wang et al.34, 35 showed that the cellular distribution of strong
complement activators within circulating phagocytes could be
impacted by the activation of the cascade.
Effect of lipid trafﬁcking pathways. In parallel, the pathways
involved in lipid trafﬁcking also appear to play important roles in
the clearance of nanoparticles, in accordance with the noticeable
enrichment of apolipoproteins (in terms of their relative
abundance compared to plasma) in the hard corona, after
exposure to in vivo conditions. Because the apolipoprotein is
undetectable in the plasma of animals deﬁcient in ApoE (ApoE
−/−)36, the model can therefore be used to monitor the impact of
this speciﬁc protein on nanoparticle circulation. Here, the pre-
sence of ApoE appears to mitigate the clearance of nanoparticles
with low PEG coverage. The depletion of ApoE resulted in the
accelerated clearance of nanoparticles with low PEG densities
(i.e., a 20–30% decrease in AUC0–6h and 20–60% increase in ke for
nanoparticles with 15 and 18 PEG chains per 100 nm2, Fig. 3b).
This effect was not observed for nanoparticles with higher PEG
coverage.
ApoE is among the most abundant proteins detected in the
proteomics experiment, and appears to preferentially interact
with the surface of the nanoparticles (Supplementary Fig. 6). In
knockout animals, the absence this protein has a substantial
impact on the protein corona, and favors faster blood clearance,
conceivably due to a higher relative contribution of opsonins. The
effect is potentially more visible with nanoparticles with low-
steric protection, given that they intrinsically adsorb higher
quantities of ApoE (Supplementary Fig. 7). To assess this
hypothesis, nanoparticles with 15 PEG chains per 100 nm2 were
Fig. 3 Circulation proﬁles in different mouse models highlight the role of different proteins on the clearance of nanoparticles. a For all nanoparticles, the
circulation proﬁles between wildtype and C3−/− animals are similar. This suggests that the complement cascade is not involved in the clearance of
nanoparticles, even those with very low steric protection and fast clearance. b The absence of ApoE accelerates the clearance of nanoparticles with fast
intrinsic clearance. This suggests that when steric protection is low, interactions with ApoE prevent clearance-enhancing proteins from adsorbing on the
nanoparticles. This effect is not observable for nanoparticles with higher PEG densities. c Similar to ApoE, pre-adsorption of clusterin on the surface of
nanoparticles with low PEG densities decreases clearance. Clusterin does not appear to inﬂuence nanoparticles with slower intrinsic clearance rates.
d In LDLR−/− animals circulation times are prolonged, with augmented blood exposures for all nanoparticles. This suggests direct involvement of LDLR
on the clearance of nanoparticles. Values are means± SD (n= 4–13). *p< 0.05 as determined by t-test, **p< 0.05 as determined by Mann–Whitney (non-
parametric) test
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incubated in plasma from ApoE−/− and control animals. When
these pre-opsonized nanoparticles were injected into C57Bl/6
mice, nanoparticles coated with plasma from ApoE−/− animals
had a 1.3-fold lower blood exposure compared to those coated
with normal plasma (Supplementary Fig. 10). This further
supports the idea that, for nanoparticles with low PEG densities,
ApoE plays a dysopsonic role. It should be emphasized that
additional mechanisms may also be involved in the changes
observed in vivo, as the elimination of ApoE protein may have
multiple downstream effects and can change other proteins in
plasma as well. In comparison, in nanoparticles with higher PEG
density and slower intrinsic clearance, ApoE represents a lower
relative abundance in the protein corona; the changes in the
corona composition after depleting ApoE are therefore compara-
tively smaller.
Recently, Schöttler et al. elegantly highlighted the possible role
of another apolipoprotein, clusterin (also known as ApoJ), in
preventing the uptake of sterically protected nanoparticles by
macrophages37. In the current study, pre-incubation with
clusterin before injection increased the in vivo blood exposure
of nanoparticles with fast intrinsic clearance (Fig. 3c). However,
the enrichment of clusterin on the surface of nanoparticles with
higher PEG densities did not signiﬁcantly alter their blood
circulation (Fig. 3c). Similar to ApoE, clusterin appears to shield
nanoparticles with insufﬁcient PEG coverage against opsoniza-
tion, but fails to affect the circulation of nanoparticles that have
greater constitutive steric protection. However, one must note
that in this experimental setting, only fairly strong interactions
would prevent exogenous proteins from desorbing from the
nanoparticle surface upon contact with the bloodstream. To that
point, Chen et al.38 showed that the complement factor C3 could
desorb from the surface of nanoparticles, despite being covalently
attached to the nanoparticle corona.
The effect of ApoE on nanoparticles with low PEG densities
contrasts with the results obtained in mice deﬁcient in the LDL
receptor (LDLR−/−). Like other knockout animals, these mice
show undetectable hepatic levels of LDLR39. Depletion of the
cellular receptor resulted in lower clearance for all nanoparticles,
with a 1.2-fold to 1.7-fold increase in AUC0–6h and a 1.1-fold to
1.6-fold decrease in ke (Fig. 3d). Physiologically, LDLR is a
cellular protein responsible for receptor-mediated endocytosis of
lipoproteins coated with ApoE and ApoB10040. To assess whether
ApoB100 affects clearance, nanoparticles were incubated in
plasma from LDLR−/− ApoB100only mice, which have 10-fold
higher ApoB100 levels than wild-type animals41. For all
nanoparticles tested, the blood circulation proﬁles remained
similar to the controls (Supplementary Fig. 10), suggesting that
the impact of ApoB100 on nanoparticle clearance is minimal.
This is not surprising in light of the lower intrinsic afﬁnity of that
protein for LDLR39.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is
another physiological ligand of LDLR that downregulates the
receptors by triggering their internalization and trafﬁcking to
lysosomal vesicles42. Within 60 min of intravenous injection,
small doses of PCSK9 transiently reduce the levels of LDLR in the
liver by 80%42. Here, pre-dosing animals with 16 µg of
recombinant mouse PCSK9 before the administration of
nanoparticles conﬁrmed the role of LDLR receptors in nano-
particle clearance: animals receiving the recombinant protein
showed longer nanoparticle circulation times compared to
untreated wild-type animals (1.2 to 1.7-fold higher AUC0–6h
and 1.1–1.4 lower ke) (Supplementary Fig. 11). Similar to the
results obtained in LDLR−/− mice, this effect was noticeable for all
90-nm nanoparticles, irrespective of PEG density. One dose of
PCSK9, given 60 min before the injection of nanoparticles, could
hardly alter the lipid proﬁle of wild-type animals and signiﬁcantly
change the interactions between proteins and nanoparticles.
These ﬁndings therefore strongly support the direct involvement
of interactions with LDLR in the clearance of nanoparticles from
the bloodstream.
Discussion
In the current study, a library of clinically relevant nanoparticles
allowed the identiﬁcation of an effective threshold of PEG
density, which appears to toggle between fast and slow clearance
over a broad range of diameters. Combinatorial synthesis and
methodical 1H-NMR characterization provide blueprints to
engineer nanoparticles with different diameters but similar
circulation times, at least during the six ﬁrst hours following
injection. The availability of such systems might stimulate many
fundamental studies on the biological fate of nanoparticles. Our
ﬁndings also conﬁrm that surface properties are very important
determinants of early interactions with the host’s defense
mechanisms, arguably more than size, when nanoparticles
are initially introduced into the bloodstream. Even within the
relatively short time frame studied, blood exposure varied up
to 7-fold between short-circulating and long-circulating nano-
particles. Given the complexity of clearance mechanisms, in vivo
pharmacokinetics proved an efﬁcient tool to highlight these
differences and supplement other work elucidating the complex
interactions at the nano-bio interface1, 6. Animals with different
protein phenotypes and knockout mouse models prove valuable
to study the role of the in vivo protein adsorption on the removal
of nanoparticles from the bloodstream. In that context, ApoE
exhibited distinct functions on nanoparticles with low and high
PEG densities. While it appears to protect nanoparticles with
poor steric protection against rapid opsonization upon entry into
the bloodstream, it also seems to act as a potential ligand for
LDLR on all nanoparticles. The involvement of LDLR in the
clearance of nanoparticles was conﬁrmed using two different
models. Despite the fact that ApoE is likely involved in these
interactions, it still remains unclear whether the presence of the
apolipoprotein is totally indispensable. As novel therapeutic
platforms are developed to treat cardiovascular diseases43, the
impact of serum lipids on the clearance of nanoparticles might
become increasingly important. In parallel, our ﬁndings in
complement-deﬁcient animals shed light on the relevance of this
cascade for PEGylated nanoparticles, at least from the perspective
of clearance in naive mice. Our results suggest that complement
activation cannot be the sole predictor of circulation times
in mice given that the biological fate of both short-circulating and
long-circulating nanoparticles appeared unaffected by disruption
of this cascade. The biological relevance of the complex interac-
tions between nanoparticles and this cascade of the innate
immunity are still being unraveled38, especially in mice where
instability of certain activation pathways has been highlighted35.
Further studies are also required to understand the role of this
cascade with regard to clearance after multiple doses of nano-
particles44 or with regard to possible pseudo-allergic reactions in
patients45. Overall, a better understanding of the clearance
mechanisms of nanoparticles and improved control over their
circulation times might help engineer more efﬁcacious systems,
whether they are utilized for in vivo imaging46, tumor targeting47,
or other biomedical applications48.
Methods
Polymer synthesis. PEG–PLGA copolymers were synthesized by a semi-batch
ring-opening polymerization of D,L-lactide and glycolide at room temperature
using mPEG5k-OH as an initiator and 1,8-diazabicycloundec-7-ene (DBU) as a
catalyst49. In a typical polymerization, after drying the initiator and monomers
under vacuum overnight, mPEG5k-OH (0.134 mmol) and D,L-lactide (10.32 mmol)
were solubilized in ~40 ml anhydrous dichloromethane. In parallel, a solution of
glycolide (5.16 mmol) was prepared using 7 ml anhydrous tetrahydrofuran (THF).
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Upon initiation of the polymerization by introduction of DBU (0.134 mmol),
the glycolide solution was immediately added at a rate of 0.7 ml min−1 using a
syringe pump. After 10 min, the polymerization was stopped by addition of benzoic
acid (1.5 mmol). The solvent was removed by rotary evaporation, and the polymer
was precipitated twice in cold diethyl ether and dried over vacuum. 1H-NMR
(CDCl3, 400 MHz): δ 1.58 p.p.m. (159 H, C(CH3)H), 3.37 p.p.m. (3 H,
H3COCH2CH2), 3.64 p.p.m. (444 H, OCH2CH2), 4.82 p.p.m (114 H, OCH2CO),
5.19 p.p.m. (53 H, OCH(CH3)CO). The polymers used in the preparation of the
nanoparticles are presented in Supplementary Table 2.
Nanoparticle preparation. Nanoparticles were prepared by nanoprecipitation
from acetonitrile solutions12. Brieﬂy, polymer precursor solutions were mixed at
different ratios and added dropwise to 8–12 ml of water under stirring. The
polymer concentration, stirring speed, and volume of water were modiﬁed to
obtain particles of the desired size. To enable tracking of nanoparticles in vivo,
small quantities of 14C-labeled PLGA polymer (Mn around 20,000, Moravek
Biochemicals) were integrated into the polymer mixtures. For the preparation of
55-nm nanoparticles with low PEG density, a microﬂuidic rapid nanoprecipitation
method was used19, 50. Nanoparticles were puriﬁed and washed with water at
least four times using an ultraﬁltration device (molecular weight cut-off 100,000)
and ﬁltered on a 0.22 µm ﬁlter before injection. The nanoparticles’ size (Z-average),
size distribution (polydispersity index), and zeta potential were measured before
and after puriﬁcation by dynamic light scattering at 22 °C with a 173 backscatter
angle, using a Malvern Zetasizer Nano ZS (Malvern Instruments, Westborough, MA).
1H-NMR characterization of the nanoparticles. The PEG content in the
nanoparticle and in the outside shell were determined by 1H-NMR spectroscopy by
modiﬁcation of a method described elsewhere13. Generally, the methylene protons
of PEG (3.6 p.p.m.) were quantitatively compared to the protons of the lactic
(1.6 and 5.2 p.p.m.) and glycolic repeating units (4.8 p.p.m.) to determine how
much PEG was present in the blends forming the nanoparticles. To determine the
amount of PEG in the shell, a ﬁrst reading was done in D2O and compared to the
spectra obtained in D2O/d3-ACN solvent mixtures. In the former, only the PEG
protons (3.6 p.p.m) are observed, while in the latter, the whole polymer being
soluble, all protons are visible. To compare spectra, 1 wt% trimethylsilyl propanoic
acid (TMSP) was used as an internal standard. The density of the PEG shell was
calculated as described elsewhere14, using the PEG content (percent by mass), a
polymer density of 1.2 g cm−3, a PEG molecular weight of 5000 g mol−1, and the
surface (cm2) and volume (cm3) of a nanoparticle calculated from the Z-average.
Results from the nanoparticle synthesis and characterization are presented in
Supplementary Table 3.
In vivo studies. All animal experiments were conducted using institutionally
approved protocols at MIT (IACUC) and Université Laval (Canadian Council on
Animal Care standards and Animal Research: Reporting In Vivo Experiments
guidelines). Healthy animals were housed in a controlled environment (22°C, 12 h
day/night cycle) with ad libitum food and drink access. In a typical experiment,
male mice (25–29 g) or Sprague-Dawley rats (220–240 g) were intravenously
injected by the subclavian vein under isoﬂurane anesthesia (2.5 %) with 60 mg kg−1
of nanoparticles (20 mg kg−1 for rats). During the following 6 h, ~30–50 µl of blood
(200–300 µl for rats) was collected via the saphenous vein (0.25, 0.5, 1, 2, 4 h), as
well as through a terminal cardiac puncture (6 h). At the end of the experiment,
animals were euthanized by a cardiac perfusion of ~3 ml of phosphate-buffered
saline solution (pH 7.4, 3 mM phosphate, 150 mM sodium chloride) and organs
were collected. Biological samples were digested at 60 °C (Solvable, Perkin Elmer,
Waltham, MA), bleached with 30% hydrogen peroxide, and assessed by scintilla-
tion counting (Hionic Fluor, Perkin Elmer, Waltham, MA). To assess the protein
corona after in vivo exposure, Balb/c mice were injected with nanoparticles with 15,
18, 25, and 45 PEG chains per 100 nm2. Fifteen minutes after injection, the
radiolabeled nanoparticles were recovered by cardiac puncture and isolated
from the blood using size-exclusion chromatography (Sephacryl S-400 HR) and
ultraﬁltration (Vivaspin, MWCO 1000 kDa). The amount of protein on the surface
of the nanoparticle was quantiﬁed using the 660 nm protein quantiﬁcation assay
(Thermo, Waltham, MA).
In speciﬁed experiments, nanoparticles were preincubated at 37 °C for 30 min,
with EDTA-containing plasma from C57Bl/6 (JAX #027), ApoE−/− (JAX #2052),
LDLR−/− ApoB100only (JAX # 3000, kind donation of Dr. Andre Marette, Institut
Universitaire de Cardiologie et de Pneumologie de Quebec Research Center) or
mouse recombinant clusterin (R&D systems, Minneapolis, MN). The nanoparticle
concentration was around 20 mgml−1 in 50% plasma or 100 μg ml−1 clusterin.
Proteins, including mouse recombinant PCSK9 (Speed Biosystems, Gaithersburg,
MD), were diluted according to the manufacturer’s instructions. In speciﬁed
experiments, 16 μg of PCSK9 were injected 1 h before nanoparticle administration.
The number of animals used in each experiment is presented in Supplementary
Table 3.
Pharmacokinetic parameters. Non-compartmental analysis of the pharmacoki-
netic parameters were calculated from blood concentration (%ID per gram of
blood) vs. time proﬁles48. The concentration at time 0 (C0) was obtained from the
Y-intercept of linear least-squares regression on the semilog plot of the blood
concentration vs. time curve, using the ﬁrst points of the curve. The volume of
distribution (Vd) was obtained from the ratio of the injected dose (100%) over C0.
The trapezoidal method, from 0 to 6 h, was used to calculate the AUC0–6h values.
The ratio of clearance (dose/AUC0-inf) over Vd afforded an estimated elimination
constant (ke).
Statistics. Statistics were computed with GraphPad Prism 6. Standard unpaired
t-test or Mann–Whitney test (non-parametric, when samples failed normality or
equality of variance statistical tests) were used to test for statistical signiﬁcance
between groups. A value of p < 0.05 was considered signiﬁcant.
Data availability. Proteomics data is deposited on the ProteomeXchange
repository (see Supplementary Methods for login details). Supplementary Table 5
presents raw data from the pharmacokinetics experiments. All other data is
available from the authors upon reasonable request.
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